52 results about "Pneumonocyte" patented technology

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention discloses hydrogel bio-ink, a preparation method of the hydrogel bio-ink, a 3D printing biodegradable airway stent and application of the 3D printing biodegradable airway stent. The preparation method comprises the following steps that S1, lung tissue is subjected to freeze thawing, slicing, sequential decellularization of SDS and TritonX-100, air drying, smashing and cryopreservation, and a lung extracellular matrix is obtained; s2, performing sterilization and pepsin treatment on the lung extracellular matrix prepared in S1 to obtain a pretreated lung extracellular matrix; and S3, mixing methyl propionylated gelatin and an alginate solution, pouring the mixture into solid gel, gelatinizing the solid gel, and adding the pretreated lung extracellular matrix to prepare the hydrogel bio-ink. The prepared pig lung acellular extracellular matrix does not have an obvious nuclear structure, and DNA (Deoxyribonucleic Acid) determination shows that the concentration of an acellular group is obviously reduced (P is less than 0.01); along with the increase of the dECM concentration, the porosity is reduced, and the degradation time is prolonged; the airway stent is printed in a 3D biological printing mode, no obvious cytotoxicity (P is larger than 0.05) exists in a cytotoxicity experiment, and the mechanical property part of the airway stent is similar to that of a silicone stent.

The present invention relates to a compound of Formula 1, a preparation method thereof, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The compound of Formula 1 according to the present invention can exhibit cell necrosis and ferroptosis inhibitory efficacy in various cells such as heart, kidney, nerve, retina, liver, or lung cells, and accordingly, can be usefully used for prevention or treatment of cell necrosis or ferroptosis-related diseases

The present disclosure provides a variant AAV capsid protein that confers tropism to lung cells and recombinant adeno-associated viruses comprising the variant AAV capsid protein and pharmaceutical compositions comprising same and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of pulmonary disorders.

The invention discloses a construction method and application of a human lung 3D cell microsphere and a human pulmonary fibrosis 3D organoid. The construction of the human lung 3D cell microspheres comprises the following steps: respectively digesting human primary fibrosis cells and human II-type alveolar epithelial cells which are subjected to adherent culture into single cells; mixing digested human primary fibrotic cells, human II-type alveolar epithelial cells and THP-1 macrophages subjected to suspension culture according to a cell number ratio of 1: 1: 1, so as to obtain a cell precipitate; and preparing the cell precipitate into cell matrigel microspheres by using a T-type microfluidic technology, and culturing to obtain the human lung 3D cell microspheres. And further inducing the human lung 3D cell microspheres by using a human lung organoid culture medium containing 50ng / mL of TGF-beta for 24-48 hours to obtain the human pulmonary fibrosis 3D organoid. According to the invention, 3D cell microspheres with human normal lung cell characteristics and protein expression can be formed within 3 days, and pulmonary fibrosis 3D organs can be obtained after short-time induction.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The present invention provides processes for producing a bioengineered lung (BEL) from an acellular lung matrix that has been treated with growth hormones, seeded with primary lung cells, and cultured in a bioreactor. Also provided are BELs and methods of transplanting the BEL into a subject in need of a lung transplant, and methods for using BELs for the study of the lung microbiome and its role in lung development and remodeling.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (RM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker 5 expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

The application belongs to the technical field of biological medicine, and particularly relates to the use of a lung extracellular matrix hydrogel in the preparation of a lung injury repair material. The application grafts methacrylic anhydride groups on a lung tissue-derived extracellular matrix, and provides a lung extracellular matrix hydrogel which can be rapidly photo-crosslinked, has high stability, effectively promotes angiogenesis, and prevents postoperative leakage. The photo-crosslinked lung extracellular matrix hydrogel of the application is applied to a lung injury animal model, significantly promotes angiogenesis, promotes alveolar regeneration, and also significantly reduces the fibrosis level. Compared with a sealing agent alpha-cyanopropyl acrylate gel and a fibrin glue which are used in clinical application, the photo-crosslinked lung extracellular matrix hydrogel has excellent effects on repairing lung injury, provides a new strategy for repairing traumatic and iatrogenic lung injury, and has a good application prospect.

To provide adeno-associated variants, formulations and methods for pulmonary delivery.SOLUTION: The present disclosure provides variant AAV capsid proteins that confer tropism for lung cells, as well as recombinant adeno-associated viruses comprising the variant AAVs and pharmaceutical compositions comprising the same, and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of lung disorders. (ii) nucleic acids comprising, from 5 ' to 3 ', (a) AAV2 terminal repeats, (b) a promoter, (c) a nucleotide sequence encoding a human cystic fibrosis transmembrane conductance regulator (CFTR) or a biologically active truncated CFTR lacking amino acids 708 to 759 of the human CFTR sequence, (d) a poly-adenylation sequence, and (e) AAV2 terminal repeats.SELECTED DRAWING: None

Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.

RNAi reagents, compositions comprising RNAi reagents, and methods for inhibiting the genome of influenza A virus are described. The influenza A virus (IAV) RNAi reagents and RNAi reagent conjugates disclosed herein inhibit expression of an influenza A virus genome at a targeting portion that spans a variety of known influenza A virus genome variants that are conserved genomes, and thus are capable of inhibiting expression of a variety of influenza A virus strains. Also described are pharmaceutical compositions comprising one or more IAV RNAi agents, optionally in conjunction with one or more additional therapeutic agents. Delivery of the IAV RNAi agents to lung cells in vivo provides inhibition of influenza A virus genomic expression, which can provide therapeutic benefits to subjects, including human subjects, for the treatment of various diseases, disorders and / or symptoms caused by influenza A virus infection.

Disclosed in the present invention are a compound derivative represented by formula I or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomer thereof, or a pharmaceutically acceptable salt thereof. On the basis of the application of a dual-protection strategy, diverse carrier fragments are introduced at the 5-hydroxyl group and hydroxylamine group of the N4-hydroxycytidine molecule to develop an N4-hydroxycytidine prodrug. Such a modification enhances the affinity for a pulmonary cell membrane (phospholipid membrane), rendering the physicochemical properties of the drug suitable for the physiological environment of lung tissue. Therefore, the compound of the present invention has a broad application prospect in the aspect of broad-spectrum anti-respiratory viruses.

The present disclosure provides a system for growing and modeling lung cells in organoid culture, and the method of using it.This document discloses the chemically defined conditions for lung stem cell proliferation, maintenance and differentiation in ex vivo organoid culture.These defined culture conditions provide the means for studying cell type specific effects and for high-throughput pharmacogenomics research to discover drugs for treating disease.

The invention relates to the technical field of tuberculosis vaccines, in particular to a tuberculosis VLP nanoparticle vaccine and preparation and application thereof. According to the tuberculosis VLP nanoparticle vaccine, through up-regulation of Th1 type, Th2 type and TH17 type cellular immune response and down-regulation of Treg cellular immune response, the H37Rv growth inhibition ability of splenic lymphocytes and lung cells in vitro is enhanced, and the cellular immune response induced by EPPE + mi3 / AS01E and the H37Rv growth inhibition ability of the cells in vitro are higher than those of BCG and a corresponding subunit vaccine EPPE / AS01E; in addition, the EPPE + mi3 / AS01E can be used as a BCG booster vaccine, and the cell immune response after BCG immunization and the H37Rv growth inhibition capacity of cells in vitro are improved.

Provided are plasmids comprising transcriptional control elements, including transcription factor binding motifs, telomeric repeat motifs, transcription factor repressor binding motifs and promoters for tunable protein expression in target cells; wherein the plasmid for controlled transcription in a target cell type comprises a transcription factor binding motif for NFIA and the cell expresses NFIA. In one embodiment, the cell type is lung cells and the transcription factor is Nuclear Factor IA (NFIA).

The present application relates to a lactobacillus reuteri HC1602, a bacterial agent and application thereof, and belongs to the technical field of microorganisms. Limosilactobacillus reuteri The lactobacillus reuteri (HC1602) is preserved in the China General Microbiological Culture Collection Center, with a preservation number of CGMCC No. 26890, a preservation date of March 23, 2023, and an address of the preservation agency of No. 3, Beichen West Road, Chaoyang District, Beijing. The present application also provides an application of the lactobacillus reuteri HC1602 in preparing a product for inhibiting and preventing respiratory syncytial virus and an application in preparing a product for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the present application can effectively inhibit the invasion of RSV on A549 lung cells and improve the survival rate of A549 cells.

Provided herein are lung forming progenitor cell therapies which do not require pre-conditioning treatments. Administration of the progenitor cells can replace or replenish populations of host-derived patch forming cells to reverse or inhibit fibrosis, promote healing, and improve lung function. Further disclosed herein are methods for monitoring fibrosis, and for determining whether a subject will be receptive to progenitor cell treatments.

Provided herein are lipid nanoparticle (LNP) compositions for use in delivering a payload to a lung cell of a subject. Also provided are a method for treating and / or preventing a lung disease, kits, pharmaceutical compositions, and other compositions and methods.

The present invention relates to the application of METTL3 in the preparation of drugs for preventing and treating radiation-induced lung injury. The present invention discovers that METTL3 knockdown has a preventive and therapeutic effect on radiation injury of human lung cells and lung tissues in animal models, can inhibit the epithelial-mesenchymal transition process during the occurrence and development of radiation-induced lung injury, and enhance the antioxidant and post-radiation cell proliferation abilities of lung cells. Therefore, the preventive and therapeutic drugs of the present invention are designed with METTL3 as the target gene, and have important significance and application value in dealing with nuclear and radiation accidents, nuclear emergencies, and reducing the lung radiation injury of tumor radiotherapy patients, etc.

The invention relates to the technical field of radiation protection, in particular to a dietary nutrition supplement capable of relieving radon internal irradiation damage and having a protective effect and a preparation method thereof, and the dietary nutrition supplement comprises the following raw materials: compound vitamins, nicotinamide, selenium-enriched yeast and propolis. Animal experiments prove that after the dietary nutrition supplement is taken, the dietary nutrition supplement not only is beneficial to relieving oxidative damage and apoptosis resistance caused by radon irradiation, inhibiting autophagy and relieving damage of radon daughters to lung cells, but also does not generate toxic and side effects, and achieves the purposes of safety and effectiveness.

The utility model provides a suspension cell culture and drug concentration generation integrated micro-fluidic chip, which structurally comprises culture units which are stacked in series, a liquid inlet and a liquid outlet which are mutually independent, each unit comprises a matrix, each culture layer is provided with an independent culture channel, and the micro-channel is modified by bovine serum albumin molecules. A closed loop is formed by vertical overlapping, and cell implantation is realized by a laminar flow phenomenon. And meanwhile, two driving channels are crossed with the culture channel and are separated from the culture channel by an elastic diaphragm. Two ends of the driving channel are communicated with the outside. The liquid inlet and the liquid outlet which are independent from each other automatically form a medicament with a gradient medicament concentration from the sample liquid inlet, the influence of the change of the concentration of the medicament on blood cell culture is researched, the chip suspension culture simulates the real environment of lung cells in vivo, and the bovine serum albumin molecule modification simplifies the cell implantation process. Medicaments with different concentrations are added into different channels, and the optimal concentration range is determined by observing the influence of the medicaments. The method has the advantages of high efficiency and economy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of neophytadiene in preparation of a medicine for preventing and treating premature senility of lung cells. According to the invention, the biological character change, the apparent transcriptional regulation effect and the internal molecular mechanism of the premature senility of the lung cells induced by the nano polystyrene are studied. Wherein the exposure of the nano polystyrene can induce the increase of cell premature senility phenotype, SA-beta-gal activity, ROS and SASP levels, and S-phase retardation of a cell cycle, and can activate the methylation modification of m6A and m7G of lung cell RNA, up-regulate the expression of RNA methyltransferase, promote the combination of METTL1 and a premature senility core gene, and accelerate the premature senility of cells. The neophytadiene NPT intervention can remarkably reverse ROS and SASP levels in cells, effectively relieve the cell cycle arrest degree, reverse the expression abnormity of RNA methylation regulatory enzyme, delay the premature senility process and the like. The invention provides a new thought and direction for prevention and intervention measures of nano-plastic induced lung injury.

The present disclosure relates to a use of M-CSF or G-CSF for diagnosis or treatment of pulmonary fibrosis and, more specifically, to: a marker for diagnosing the level of development or progression of pulmonary fibrosis, comprising M-CSF and / or G-CSF; and a composition for preventing or treating pulmonary fibrosis, comprising an M-CSF inhibitor and a G-CSF inhibitor as active ingredients.The present inventors have ascertained that M-CSF and / or G-CSF is a marker for development or progression of pulmonary fibrosis, and have confirmed that a composition, which comprises M-CSF and G-CSF and which binds to M-CSF and G-CSF so that the inherent mechanism thereof can be prevented, has an effect of significantly inhibiting myofibroblast hyperplasia or pulmonary fibrosis of the pulmonary cells, and thus the marker and the composition of the present disclosure are expected to be effectively usable for diagnosis, prevention or treatment of pulmonary fibrosis.

Provided herein is a lung-forming progenitor cell therapy that does not require preconditioning treatment. Administration of the progenitor cells can replace or replenish a population of host-derived patch-forming cells to reverse or suppress fibrosis, promote healing, and improve lung function. Also disclosed herein are methods for monitoring fibrosis and determining whether a subject is susceptible to progenitor cell therapy.

Described herein are compositions and methods for potent and long-lasting gene editing in a cell. The gene editing may result in an increase in function of a gene product. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. The presently disclosed compositions comprise a lipid composition, which can comprise an ionizable cationic lipid, a sterol, a phospholipid, and a selective organ targeting lipid. Also described herein are methods for treating a disease or disorder, such as a lung disease or disorder, involving the presently disclosed compositions.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The present invention belongs to the field of biomedical technology, and discloses Weissella cibaria X-5 and its application. The Weissella cibaria X-5 has a deposit number of CCTCC NO: M 20232333 and is deposited in the China Center for Type Culture Collection. The Weissella cibaria X-5 can secrete extracellular polysaccharide, and the secreted extracellular polysaccharide can significantly improve the lung function of mice with chronic obstructive pulmonary disease. It is found through observation of lung tissue sections that it can also significantly improve the level of pulmonary cell infiltration in chronic obstructive pulmonary disease, has no effect on the body weight and growth status of mice, and causes no damage to important organs, with high safety. In addition, cell experiments show that the extracellular polysaccharide can also significantly improve the expression of genes related to the MHS inflammatory response of macrophages, and has no effect on the viability of macrophages MHS. Therefore, the Weissella cibaria X-5 of the present invention and the extracellular polysaccharide secreted by it can be used to prepare drugs for alleviating and / or treating chronic obstructive pulmonary disease.

The invention belongs to the technical field of biomedicine, and particularly relates to application of lung extracellular matrix hydrogel in preparation of a lung injury repair material. A methacrylic anhydride group is grafted on a lung tissue-derived extracellular matrix, and the lung extracellular matrix hydrogel capable of being quickly photo-crosslinked is provided, is high in stability, effectively promotes angiogenesis and prevents postoperative leakage. When the photo-crosslinking lung extracellular matrix hydrogel is applied to a lung injury animal model, the generation of blood vessels is remarkably promoted, the regeneration of pulmonary alveoli is promoted, and the fibrosis level is also remarkably reduced. Compared with clinically used sealants alpha-cyanoacrylate gel and fibrin glue, the sealant has an excellent lung injury repairing effect, provides a new strategy for trauma and iatrogenic lung injury repairing, and has a good application prospect.